Drugs / Human Mesenchymal Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07512362 | May 2026 → Jun 2028 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Bernard (Barry) Baumel | Recruiting | No outcome recorded |
| Phase 2 | NCT02833792 | Jun 2016 → Jul 2024 | Alzheimer disease | Stemedica Cell Technologies, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2016-05-18 | Stemedica Cell Technologies, Inc. | Regulatory FDA Grants IND Approval To Stemedica For A Traumatic Brain Injury Phase IIa Clinical Trial stemedica.com ↗
Stemedica Cell Technologies, Inc. (Stemedica) received an FDA investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its ischemic tolerant, adult allogeneic mesenchymal stem-cells (itMSC) to treat subjects with traumatic brain injury (TBI). |
| 2015-06-09 | Stemedica Cell Technologies, Inc. | Regulatory FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s ITMSC Therapy to Treat Alzheimer’s Disease stemedica.com ↗
Stemedica Cell Technologies, Inc. received the FDA’s investigational new drug (IND) approval |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-05-18 | Stemedica Cell Technologies, Inc. | FDA Grants IND Approval To Stemedica For A Traumatic Brain Injury Phase IIa Clinical Trial stemedica.com ↗ |
| 2015-06-09 | Stemedica Cell Technologies, Inc. | FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s ITMSC Therapy to Treat Alzheimer’s Disease stemedica.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02833792 ↗ |
| Known as | hMSCs | “ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica” NCT02833792 ↗ |
| Modality | Cell therapy | “allogeneic human mesenchymal stem cells” NCT02833792 ↗ |
| Route | Intravenous | “single intravenous dose of hMSCs” NCT02833792 ↗ |